https://ab-bispec.accmed.org/weekly0.5https://ab-bispec.accmed.org/aspetti-generaliweekly0.5https://ab-bispec.accmed.org/aspetti-generali/anticorpi-bispecifici-e-linfomi-update-da-icml-2025weekly0.52025-09-12T08:04:49+00:00https://ab-bispec.accmed.org/aspetti-generali/come-cambia-il-patient-journey-dei-pazienti-con-linfomaweekly0.52025-09-04T07:29:58+00:00https://ab-bispec.accmed.org/aspetti-generali/come-cambia-il-patient-journey-dei-pazienti-con-mieloma-multiploweekly0.52025-09-04T07:29:50+00:00https://ab-bispec.accmed.org/aspetti-generali/cosa-sono-e-come-agisconoweekly0.52023-06-01T07:44:23+00:00https://ab-bispec.accmed.org/aspetti-generali/immunoconiugati-e-abbis-nel-mieloma-multiploweekly0.52025-03-06T10:17:46+00:00https://ab-bispec.accmed.org/aspetti-generali/la-gestione-clinica-degli-anticorpi-bispecificiweekly0.52024-03-06T10:24:31+00:00https://ab-bispec.accmed.org/aspetti-generali/linfomi-aggressivi-car-t-e-anticorpi-bispecificiweekly0.52025-02-19T09:34:45+00:00https://ab-bispec.accmed.org/linfoma-follicolareweekly0.5https://ab-bispec.accmed.org/linfoma-follicolare/abbis-nelle-forme-a-bassa-malignitaweekly0.52025-09-04T07:30:04+00:00https://ab-bispec.accmed.org/linfoma-follicolare/le-evidenze-scientifiche-risultati-consolidati-e-tossicitaweekly0.52023-02-14T17:10:40+00:00https://ab-bispec.accmed.org/linfoma-follicolare/nuovi-approcci-terapeutici-ruolo-degli-anticorpi-bispecificiweekly0.52025-02-19T09:34:40+00:00https://ab-bispec.accmed.org/linfoma-follicolare/posizionamento-dei-farmaci-bispecifici-e-sviluppi-futuriweekly0.52024-03-06T07:57:27+00:00https://ab-bispec.accmed.org/linfoma-follicolare/speciale-ash-2022weekly0.52023-06-01T07:50:50+00:00https://ab-bispec.accmed.org/linfoma-follicolare/speciale-icml-2023weekly0.52023-10-31T09:23:40+00:00https://ab-bispec.accmed.org/linfomi-diffusi-a-grandi-cellule-b-dlbclweekly0.5https://ab-bispec.accmed.org/linfomi-diffusi-a-grandi-cellule-b-dlbcl/abbis-nelle-forme-ad-alta-malignitaweekly0.52025-09-04T07:30:11+00:00https://ab-bispec.accmed.org/linfomi-diffusi-a-grandi-cellule-b-dlbcl/car-t-o-anticorpi-bispecifici-nei-linfomi-a-cellule-bweekly0.52025-02-19T09:34:34+00:00https://ab-bispec.accmed.org/linfomi-diffusi-a-grandi-cellule-b-dlbcl/le-evidenze-scientifiche-risultati-consolidati-e-tossicitaweekly0.52023-02-14T17:10:47+00:00https://ab-bispec.accmed.org/linfomi-diffusi-a-grandi-cellule-b-dlbcl/posizionamento-dei-farmaci-bispecifici-e-sviluppi-futuriweekly0.52024-03-06T07:57:21+00:00https://ab-bispec.accmed.org/linfomi-diffusi-a-grandi-cellule-b-dlbcl/speciale-ash-2022weekly0.52023-06-01T07:50:57+00:00https://ab-bispec.accmed.org/linfomi-diffusi-a-grandi-cellule-b-dlbcl/speciale-icml-2023weekly0.52023-10-31T09:23:45+00:00https://ab-bispec.accmed.org/progetto/boardweekly0.5https://ab-bispec.accmed.org/progetto/razionaleweekly0.52022-11-11T08:34:02+00:00https://ab-bispec.accmed.org/webinar/webinar-2024weekly0.52024-03-28T11:08:10+00:00https://ab-bispec.accmed.org/webinar/webinar-2025weekly0.52025-02-19T08:18:20+00:00